Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Single-Vial ID93 + GLA-SE Vaccine in Healthy Adults
NCT03722472Phase 1Completed
- Sponsor
- Access to Advanced Health Institute
- Start
- Oct 2018
- Primary completion
- Jun 2020
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ID93 + GLA-SE in pulmonary tuberculosis (TB) (2 arms), sponsored by Access to Advanced Health Institute. Primary endpoints: Local Injection Site Reactogenicity, Systemic Reactogenicity and 2 more. Started Oct 2018; status: completed.
02
Drugs
ID93 + GLA-SE
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on NCT03722472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03722472.